|
|
||||||||
a Congenital Heart Institute, Arnold Palmer Hospital for Children, Orlando, Florida
b University of Central Florida College of Medicine, Orlando, Florida
Accepted for publication August 25, 2009.
* Address correspondence to Dr DeCampli, Congenital Heart Institute, Arnold Palmer Hospital for Children, 50 W Sturtevant St, Orlando, FL 32806 (Email: william.decampli{at}orlandohealth.com).
| Abstract |
|---|
|
|
|---|
Methods: The records of 144 infants less than 10 kg who underwent CPB for a variety of congenital cardiac procedures were reviewed. The GLU values (at multiple intervals during and after surgery), age, weight, CPB time, ultrafiltration volume, and risk adjustment for congenital heart surgery (RACHS-1) score were recorded. Univariate and multivariate linear and binary logistic regression were used to examine the dependence of the composite outcome mortality or postoperative infection, the mechanical ventilation time (VENT time), and the length of stay (LOS), on these variables.
Results: The RACHS-1 score was the only significant predictor of the composite variable "mortality or infection" (p = 0.008). Glucose at any time was not a significant factor predicting this outcome. Lower pre-CPB GLU, younger age, and higher RACHS-1 score were significant predictors of greater LOS and VENT time.
Conclusions: In this study, post-CPB and postoperative hyperglycemia were not risk factors for postoperative morbidity and mortality after infant cardiac surgery.
| Introduction |
|---|
|
|
|---|
Some clinical reports have linked hyperglycemia to increased morbidity and mortality [5, 6, 8] while others have found no relation to adverse neurodevelopmental outcome [9, 10]. In fact, studies in piglets and cats have reported that hyperglycemia is associated with better maintenance of high energy metabolites and better preservation of brain mitochondria respiratory capacity [11, 12]. Studies of the effects of using dextrose containing solutions during infant cardiac surgery show conflicting results [6, 13].
In adult cardiac surgery, evidence shows that maintaining glucose (GLU) less than180 mg/dL is associated with better outcome [14]. Conversely, the GLU threshold for adverse outcome in children is less clear. In children, GLU between 125 mg/dL and 150 mg/dL may cause glycosuria and dehydration [15], and values exceeding 250 mg/dL are associated with worse outcome after brain injury [16]. More recent published literature [17] suggests that maintaining the GLU level between 110 mg/dL and 126 mg/dL is associated with better outcome after complex cardiac surgery. Furthermore, intensive insulin therapy during cardiopulmonary bypass has been shown to attenuate the systemic inflammatory response after infant cardiac surgery [18].
Given the conflicting conclusions of the aforementioned studies, there is a need for additional evidence as to the clinical effects of hyperglycemia during and after congenital cardiac surgery. We analyzed whether GLU values during and after congenital cardiac surgery were associated with mortality or three other measures of morbidity in the postoperative period.
| Patients and Methods |
|---|
|
|
|---|
Anesthesia and CPB Protocol
We induced and maintained anesthesia using midazolam, fentanyl, pancuronium, and sevoflurane. Propofol was used in patients expected to be extubated shortly after surgery. We gave dexamethasone (1 mg/kg) upon anesthesia induction before CPB was instituted. Insulin was not used in any patient during the operative period. We treated plasma GLU lower than 60 mg/dL with dextrose 25% (1 cc/kg) during the operative period. Hyperglycemia was sporadically treated with insulin (2 subjects) in the cardiac intensive care unit (CICU).
The CPB circuit consisted of the Baby RX oxygenator and venous reservoir (Terumo, Ann Arbor, MI), Capiox AF02 arterial line filter (Terumo),
inch tubing arterial-venous loop, and pediatric Bio-pump BP-50 (Medtronic, Minneapolis, MN). Our CPB circuit prime volume used for patients up to 10 kg is approximately 330 cc. Prime solution consisted of whole blood or a combination of washed pack red blood cells and fresh frozen plasma depending on the availability of the former. Plasma-Lyte A (Baxter International Inc, Deerfield, IL), sodium bicarbonate (15 mEq), heparin (2,000 units), calcium chloride (200 mg), and aprotinin (2 cc/kg) were also added. Hyperoxia (FiO
2 = 100%, PaO
2 > 400 mm Hg, and venous saturations >75%) was used and acid-base management included the use of pH stat techniques for patients cooled below 28°C and alpha stat for all others. We used continuous ultrafiltration in all cases. We did not administer supplemental dextrose during CPB and glucose was not a component of the cardioplegia solution. The cardioplegia dose was 20 mL/kg (minimum of 100 mL) induction followed by maintenance doses of 10 mL/kg (minimum of 50 mL).
Data Collected
Glucose was recorded at the following times: pre-CPB, at CPB initiation, near completion of CPB, post-CPB, upon arrival to the CICU, and last value obtained within the first and second 24 hour periods (last GLU day 1 and last GLU day 2, respectively. For each patient, age, operation, pump prime glucose concentration (prime GLU), CPB time, ultrafiltration volume, serum lactate, risk adjustment for congenital heart surgery (RACHS-1) category, incidence of electroencephalograph (ECG)-evident seizures, duration of mechanical ventilation (VENT time), length of stay (LOS), evidence of tracheal, blood, urine and wound infection, and in-hospital or 30 day mortality were recorded.
Statistical Methods
Univariate regression was carried out to determine single variable associations between each of the independent variables (seven GLU values, age, BYAGE, CPB time, prime GLU, ultrafiltration volume, and RACHS category) and the outcome variables (mechanical ventilation time, length of stay, and the composite of mortality + incidence of infection [MORTINF]). The latter composite score was chosen because a power analysis showed that the mortality rate itself was too low to determine its risk factors within the limits chosen for type I and II errors (
= 0.05 and β = 0.1), respectively, for the sample size of 144. We treated age as a dichotomous variable (BYAGE) (
30 days, >30 days) but also checked for any significant differences when using age as a continuous variable. All risk factors with a p value less than 0.1 were then entered into a multivariate (linear regression) analysis for continuous dependent variables (ventilator time, length of stay), or binary logistic regression for the categoric variable MORTINF to calculate the final determinates of risk. For continuous dependent variables, the tolerance (T) of each covariant was calculated to determine important multicollinearity, with T less than 0.4 taken to indicate the latter possibility. For logistic regression the receiver operating curve (ROC) was used to estimate the C-statistic, or predictive power for the solution. Univariate regression, Student t test, and Pearson or Spearman correlation were used to compare other pairs of variables. We used SPSS version 14.0 (SPSS Inc, Chicago, IL) as our statistical analysis package. Measurements are expressed as mean and standard deviation and a p value less than 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
30 days old, n = 63; B = >30 days old, n = 81) was observed at the following periods: near CPB completion (A 133.73 ± 35.62; B 160.33 ± 32.24; p < 0.05); post-CPB (A 144.61 ± 40.34; B 161.23 ± 37.76; p < 0.05); upon arrival to the CICU (A 151.38 ± 43.81; B 142.20 ± 40.08; p < 0.05); end of day 1 (A 130.40 ± 35.54; B 114.32 ± 28.42; p < 0.05); and end of day 2 (A 111.48 ± 34.60; B 106.01 ± 28.60; p < 0.05). Thus, neonates demonstrated a lower GLU intraoperatively compared with non-neonates, but higher GLU level upon arrival to the CICU and through the 48 hours postoperative than non-neonates. The GLU at CPB initiation correlated weakly with prime GLU (Spearman r = 0.26, p = 0.001) and was even more weakly correlated with subsequent GLU measurements. Neither post-CPB GLU nor GLU on arrival to CICU correlated with CPB time (Spearman r = –0.06 and 0.07, respectively).
|
|
|
Univariate statistics for the outcome variable MORTINF are shown in Table 3. Only BYAGE, age, and RACHS-1 score were significant univariate determinants. In particular, no GLU value was a significant predictor of mortality or infection. In the multivariate logistic regression only RACHS-1 score was a significant determinant (p = 0.008). The odds ratio for death or infection was 1.47 (95% confidence interval 1.1 to 2.0) for every increase by one in RACHS-1 score. The C-statistic, or area under the ROC for this solution (indicative of its predictive power) was 0.64 ± 0.05 (p = 0.01).
|
|
| Comment |
|---|
|
|
|---|
Published studies differ in the apparent effect of intraoperative hyperglycemia on clinical outcomes [8, 9, 10, 19]. Some reports suggest hypoglycemia rather than hyperglycemia to be related to electroencephalographic seizures, slower electroencephalographic recovery, and an increase risk of adverse events [9, 19]. In other studies hyperglycemia has not been associated with adverse neurodevelopmental outcome [9, 10]. One study found an association between hyperglycemia and morbidity and mortality [8]. A recent report found GLU less than 109 mg/dL and greater than 143 mg/dL associated with mortality and the duration of time in which GLU greater than 126 mg/dL during the first 72 hours postoperative associated with greater LOS [17]. The present study fails to show that GLU, either before, during, or after CPB, are predictors of mortality plus infection or increase duration of ventilation time. The pre-CPB glucose was a determinant of hospital LOS, with lower glucose values correlated with increased LOS. Despite the fact that the LOS solution did not suffer from significant multicollinearity, the independent variables age and pre-CPB GLU were correlated to some extent (Pearson r = 0.39). This raises the possibility that, for the patients with longest duration hospital stay, the lower glucoses were due largely to the fact that these patients were also younger. Indeed, from a mechanistic viewpoint, it is unlikely that lower pre-CPB glucose would cause longer hospital stay. However, the sample size of this cohort does not allow us to statistically prove it.
This study has several limitations. First, it is a nonblinded retrospective study. Second, we examined only short-term clinical outcome. Third, the relative small sample size did not allow us to discriminate small differences in morbidity or mortality, to analyze subgroups, or to consider additional possible risk factors. For example, it is obvious that associated noncardiac anomalies or intervening complications later in the hospital stay should influence hospital length of stay. It is unlikely, however, that the inclusion of such risk factors would cause perioperative GLU values to reenter the multivariate solution as significant covariates (risks).
In conclusion we have demonstrated that intraoperative hyperglycemia commonly occurs during infant cardiac surgery. Intraoperative hyperglycemia per se does not appear to be associated with adverse early outcomes. Hyperglycemia after infant cardiac surgery peaks early after CPB and decreases to normal values during the next 48 hours postsurgery unless other complications intervene. Thus, we find no evidence, for example, to support the aggressive use of insulin to manage early postoperative hyperglycemia after infant cardiac surgery.
| Acknowledgments |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
S. M. Schwartz, K. J. S. Anand, M. A. Portman, S. Crow, D. P. Nelson, and J. J. Zimmerman Endocrinopathies in the Cardiac ICU World Journal for Pediatric and Congenital Heart Surgery, July 1, 2011; 2(3): 400 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jaggers Invited Commentary Ann. Thorac. Surg., January 1, 2010; 89(1): 185 - 186. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |